Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 20, 2025 21:00 ET | Source: Bragar Eagel & Squire

Bragar Eagel & Squire, P.C. Is Investigating Dave, Red Cat, Perpetua, and Voyager and Encourages Investors to Contact the Firm

NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Dave, Inc. (NASDAQ:...
February 24, 2025 21:00 ET | Source: Bragar Eagel & Squire

VOYAGER ALERT: Bragar Eagel & Squire, P.C. is Investigating Voyager Therapeutics, Inc. on Behalf of Voyager Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Voyager Therapeutics, Inc....
February 23, 2021 19:45 ET | Source: The Rosen Law Firm PA

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Voyager Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline – VYGR

NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1,...
February 18, 2021 19:10 ET | Source: The Rosen Law Firm PA

ROSEN, A LEADING LAW FIRM, Encourages Voyager Therapeutics, Inc. Investors with Large Losses to Secure Counsel Before Important Deadline – VYGR

NEW YORK, Feb. 18, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1,...
February 10, 2021 16:28 ET | Source: The Rosen Law Firm PA

ROSEN, A LEADING AND RANKED FIRM, Encourages Voyager Therapeutics, Inc. Investors with Large Losses to Secure Counsel Before Important Deadline – VYGR

NEW YORK, Feb. 10, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1,...
June 01, 2017 07:04 ET | Source: Voyager Therapeutics

Voyager Therapeutics Selects Lead Clinical Candidate for Huntington’s Disease

CAMBRIDGE, Mass., June 01, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological...
May 09, 2017 16:10 ET | Source: Voyager Therapeutics

Voyager Therapeutics Reports First Quarter 2017 Financial Results and Corporate Highlights

VY-AADC01 interim Phase 1b data recently presented at American Academy of Neurology and American Association of Neurological Surgeons meetings; program on track to report 6-month data from Cohort 3...
April 25, 2017 07:02 ET | Source: Voyager Therapeutics

Voyager Therapeutics Announces Additional Results from Phase 1b Trial of VY-AADC01 for Advanced Parkinson’s Disease

Improved Functional and Quality of Life Data Presented at the American Academy of Neurology (AAN) Meeting in Boston, MA Surgical Delivery Data Presented at the American Association of Neurological...
August 11, 2016 07:05 ET | Source: Voyager Therapeutics

Voyager Therapeutics Provides Second Quarter 2016 Investor Update

VY-AADC01 Phase 1b Study for Advanced Parkinson’s Disease On Track to Report Six-Month Safety, Motor Function, and Biomarker Data from Cohorts 1 and 2 by Year-End 2016 Pipeline Advances with...